18 June 2015
NICE has asked for further information from the company to make a final decision on the use of idelalisib in combination with the drug rituximab for adults with chronic lymphocytic leukaemia whose disease is refactory to other treatments when it is not considered appropriate to treat again with previous therapies.
Technology appraisal guidance [TA343] Published today June 2015
You can access full guidance details on the NICE website here:http://www.nice.org.uk/guidance/ta343
Obinutuzumab (Gazyvaro), given with a drug called chlorambucil, is recommended as a possible treatment for adults with untreated chronic lymphocytic leukaemia only if:
Technology appraisal guidance [TA344] Published today June 2015
You can access full guidance details on the NICE website here:http://www.nice.org.uk/guidance/ta344
Ofatumumab (Arzerra) given with a drug called chlorambucil is recommended as a possible treatment for people with untreated chronic lymphocytic leukaemia if treatments containing fludarabine or bendamustine are not suitable.
What does this mean for me?
The Scottish Medicines Consortium (SMC) has published advice accepting Ofatummumab for use in NHS Scotland to treat CLL
Following a full submission assessed under the orphan process
ofatumumab (Arzerra®) is accepted for restricted use within NHS Scotland.
Idelalisib (Zydelig) has been accepted for restricted use by NHS Scotland. you can read more & access the full guidance PDF from the download on the SMC website.
CLLSA have participated in the consultation process, it is rewarding to see this now gain approval.
SMC intitial guidance details:
following a full submission
It was a privilege to be given the opportunity to kick off the day, with a welcome and provide news of CLLSA milestones and achievements of 2014. The Association, patient community and wider "CLL family" have achieved a great deal together during 2014. It was a pleasure to share this.
CLLSA at NICE and preliminary NICE guidance for two new CLL treatments.
The CLLSA regulatory appraisals volunteer group are participating in six NICE consultations. CLLSA representatives commented on the following NICE documents and attended the Scope, Appraisal workshops and participated on appraisal committees to date this year this has resulted in the excellent news that two new treatments have already received preliminary recommendation by NICE for NHS treatment of CLL in England and Wales: